Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

A simple ML model training example.

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 4.1%, or $19.25, after results are released.

Vertex Pharmaceuticals (NASDAQ ... One is the company's efforts to make the drug affordable, for example, offering a savings program that allows eligible patients to pay as little as $30 dollars ...

Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog. Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key ...